Speaker at Pharmaceutics and Novel Drug Delivery Systems 2023 - Tarek Aboul Fadl
Assiut University, Egypt
Title : Thiadiazine-2-thione derivatives as new carrier systems for isothiocyanates and dithiocarbamic acid with potential anticancer activities


Cancer remains a global public health concern due to its morbidity and mortality, and anticancer agents are crucial for the control and eradication of cancers. According to the International Agency for Research on Cancer. Although cancer chemotherapy has progressed in major strides in recent years, there is still an unmet need for new anti-cancer agents with good potency, diminished toxicity and ability to treat tumors that are resistant to currently known drugs.Isothiocyanates isolated from cruciferous vegetables have been identified as potent anticancer agents in animal and human epidemiological studies. They were reported to induce cell cycle arrest that nominates them as chemotherapeutic agents in cells with multidrug resistance phenotypes. Furthermore, dithiocarbamic acid derivatives have received much attention due to their cancer chemopreventive and anticancer action activities. Additionally, Tetrahydro-(2H)-1,3,5-thiadiazine-2-thione (THTT) nucleus has been verified for their different biological activities including anticancer activities. It has been postulated that the biological activity of THTT is mainly dependent on isothiocyanates and dithiocarbamic acid species that are generated in the biosystem upon hydrolysis. Encouraged by the above and in continuation of our synthetic work on THTT it seemed interesting to prompt to development of THTT as a new class of carriers to these active species of molecules.

  Audience Take Away Notes:

  • Development of a new Drug Delivery System
  • The potential of Structure-based drug design for drug discovery and Development
  • How to improve the activities of the current clinically approved drugs
  • Opening the windows for global scientific collaborations
  • Improvement of the accuracy of drug design and providing new information to assist in solving drug design problems


Prof. Tarek Aboul-Fadl has completed his PhD in Medicinal Chemistry from Assiut University, Egypt (1994) under the channel system and joint supervision scheme between Assiut University and Josai University/Japan. He performed his postdoctoral training as a postdoctoral research fellow and scientist of Pharmaceutical and Medicinal Chemistry at University of Vienna, Austria (1997- 1998), Friedrich-Alexander- Universität, Erlangen-Nürnberg, Germany (1999 and 2013) and University of Utah, USA (2001-2002 and 2004-2005). He has over 85 publications and 4 patents that have been cited over 2065 times, and his publication H-index is 23 (google_scholar), 21(Scopus). He was awarded ACDIMA Research Award for Best Scientific Research in Arab World, 2012.